OncoSil Study Reports Disease Control in Pancreatic Cancer Patients
Closing price · 2026-10-27: $0.750 · +7.14%
A peer-reviewed, single-centre study of a small, selected group of patients reported local disease control in all evaluable patients at about four months after treatment with OncoSil alongside chemotherapy; four patients later underwent surgery with clear margins. The study also reported successful implantation in all participants without implantation-related complications, but the survival findings remain exploratory and statistically immature.